LAVA Therapeutics
LVTX
LVTX was delisted on the 20th of November, 2025.
21 hedge funds and large institutions have $26.6M invested in LAVA Therapeutics in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
62% more funds holding
Funds holding: 13 → 21 (+8)
0.27% more ownership
Funds ownership: 28.91% → 29.17% (+0.27%)
22% less capital invested
Capital invested by funds: $34.1M → $26.6M (-$7.5M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Bruce & Co
Chicago,
Illinois
|
+$459K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$411K |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$229K |
| 4 |
KI
Kapitalo Investimentos
Sao Paulo,
Brazil
|
+$97.3K |
| 5 |
Renaissance Technologies
New York
|
+$86.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$794K |
| 2 |
Millennium Management
New York
|
-$179K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$17.1K |
| 4 |
AWG
Alpha Wave Global
New York
|
-$7.7K |
| 5 |
Axa
Paris,
France
|
-$5.46K |
LVTX Hedge Fund Activity: Q4 2022 in Review
21 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q4 2022, worth a combined $26.6M — down 22% from $34.1M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new LVTX positions and 1 closed out — a net gain of 8 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Bruce & Co, opening a new position worth an estimated $459K. The largest seller was Silverarc Capital Management, cutting an estimated $794K.
- 21 institutional investors held LAVA Therapeutics (LVTX) as of Q4 2022, up from 13 in Q3 2022.
- Funds reported $26.6M of LAVA Therapeutics stock for Q4 2022, down 22% quarter-over-quarter.
- 9 funds opened new LAVA Therapeutics positions in Q4 2022 and 1 closed out, a net change of +8 holders.
- The largest LAVA Therapeutics buyer in Q4 2022 was Bruce & Co, an estimated $459K added.
- The largest LAVA Therapeutics seller in Q4 2022 was Silverarc Capital Management, an estimated $794K sold.
Based on aggregated 13F filings for Q4 2022.